VIM and lung carcinoma: Inhibition of LINC00511 increased epithelial biomarker (E-cadherin) expression and suppressed mesenchymal biomarkers (vimentin, snail, N-cadherin) to inhibit epithelial–mesenchymal transition of lung cancer [18].